2010-01-14 00:16:52 –
VertiFlex, Inc., a leading innovator of minimally invasive and motion preserving spinal surgery technologies, announced that it has successfully completed the first human implantation of its Shockwave Dynamic Stabilization System. The surgery was performed by Dr. Stefan Hellinger at the ISAR Klinik in Munich, Germany.
The Shockwave System is the company’s next generation Dynamic Rod that provides the most motion of any dynamic rod while also limiting extension for proper load sharing.
“I am very pleased with the outcome of this surgery,” says Dr.
Hellinger. “I have a long history with Dynamic Rods and I am excited about Shockwave because it allows for significant controlled movement through normal anatomical motion, yet does not permit hyper-mobility.
The truly percutaneous implantation of this device also reduces the burden to the patient. I believe the Shockwave Dynamic Rod will provide distinct benefits to a set of my patients over the currently available Dynamic Rods.”
The Shockwave Dynamic Rod allows for 4 mm of unconstrained axial translation with an additional 20° of conical rotation. The Shockwave Rod is designed to allow patients a normal range of motion while providing hard stops that limit excessive motion and thereby relieve symptoms.
“The Shockwave Dynamic Rod System represents another evolution in VertiFlex’s long line of leading percutaneous and motion preserving spinal implants,” says Earl R. Fender, President & CEO of VertiFlex. “We are excited about the future of this unique system and are looking forward to closely monitoring initial patient outcomes.”
Shockwave is currently CE marked and under limited release in Europe and is not commercially available in the United States.
About VertiFlex, Inc.
VertiFlex is a privately held medical device company dedicated to the advancement of minimally invasive and motion preserving technologies for disorders of the spine. Founded in 2005 and headquartered in San Clemente, CA, VertiFlex currently markets products globally in addition to conducting a pivotal human IDE trial for a next generation interspinous spacer. The Superion interspinous spacer is a percutaneous titanium implant that fits between the spinous processes in the lumbar spine. Superion received CE mark in 2007, and is currently undergoing a pivotal FDA clinical trial for the minimally invasive treatment of spinal stenosis. Current investors include Aberdare Ventures, Alta Partners, Morgenthaler, and New Enterprise Associates.
VertiFlex, Inc.Scott LynchVice President, Global Marketing(949)
940-1400 email@example.com : mailto:firstname.lastname@example.org www.vertiflexspine.com : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww ..